Patents by Inventor Stephen F. Brady
Stephen F. Brady has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7479372Abstract: The present invention provides synthetic ?-secretase peptide substrates useful in various assays for measuring ?-secretase activity. Antibodies that recognize the synthetic substrates and uses of the antibodies in various assays are disclosed. The herein disclosed peptide substrates are hydrolyzed at rates substantially faster than the attendant Swedish mutant APP from which the substrate sequences are derived.Type: GrantFiled: September 19, 2006Date of Patent: January 20, 2009Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, James E. Bruce, Elizabeth Chen-Dodson, Victor Garsky, Yueming Li, Mohinder Sardana, Jules A. Shafer, Xiaoting Tang
-
Patent number: 7205336Abstract: The present invention provides compounds that are inhibitors of the proteolytic activity of the enzyme ?-secretase, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions comprising the compounds, processes for making the compounds, and methods of using the compounds to treat Alzheimers disease.Type: GrantFiled: May 14, 2003Date of Patent: April 17, 2007Assignee: Merck & Co., Inc.Inventors: Ming-Tain Lai, Ming-Chih Crouthamel, Stephen F. Brady
-
Patent number: 7132401Abstract: The present invention provides synthetic ?-secretase peptide substrates useful in various assays for measuring ?-secretase activity. Antibodies that recognize the synthetic substrates and uses of the antibodies in various assays are disclosed. The herein disclosed peptide substrates are hydrolyzed at rates substantially faster than the attendant Swedish mutant APP from which the substrate sequences are derived.Type: GrantFiled: May 17, 2002Date of Patent: November 7, 2006Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, James E. Bruce, Elizabeth Chen-Dodson, Victor Garsky, Yueming Li, Mohinder Sardana, Jules A. Shafer, Xiaoting Tang
-
Publication number: 20040081659Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).Type: ApplicationFiled: August 15, 2003Publication date: April 29, 2004Applicant: Merck & Co., Inc.Inventors: Stephen F. Brady, Dong-Mei Feng, Victor M. Garsky
-
Patent number: 6174858Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).Type: GrantFiled: November 17, 1998Date of Patent: January 16, 2001Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, Dong-Mei Feng, Victor M. Garsky
-
Patent number: 6127333Abstract: Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by a diamine linker between the oligopeptide and vinblastine. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).Type: GrantFiled: July 9, 1998Date of Patent: October 3, 2000Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, Victor M. Garsky, Joseph M. Pawluczyk
-
Patent number: 5798377Abstract: A compound which inhibits human thrombin and where has the structure ##STR1## such as ##STR2##Type: GrantFiled: October 21, 1996Date of Patent: August 25, 1998Assignee: Merck & Co., Inc.Inventors: William C. Lumma, Thomas J. Tucker, Keith M. Witherup, Stephen F. Brady, Willie L. Whitter, Joseph P. Vacca, Craig Coburn, Jules A. Shafer
-
Patent number: 5792779Abstract: Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: ##STR1## for example: ##STR2##Type: GrantFiled: February 19, 1997Date of Patent: August 11, 1998Assignee: Merck & Co., Inc.Inventors: Philip E. Sanderson, Terry A. Lyle, Joseph P. Vacca, William C. Lumma, Stephen F. Brady, Thomas J. Tucker
-
Patent number: 5714485Abstract: Compounds of the invention have the following structure: ##STR1##Type: GrantFiled: January 16, 1997Date of Patent: February 3, 1998Assignee: Merck & Co., Inc.Inventors: William C. Lumma, Roger M. Freidinger, Stephen F. Brady, Philip E. Sanderson, Dong-Mei Feng, Terry A. Lyle, Kenneth J. Stauffer, Thomas J. Tucker, Joseph P. Vacca
-
Patent number: 5672582Abstract: 4-substituted cyclohexylamine derivatives which are thrombin catalytic site inhibitors and which are useful as anticoagulants. These compounds show selectivity for thrombin over other trypsin-like enzymes and have oral bioavailability.Type: GrantFiled: October 12, 1994Date of Patent: September 30, 1997Assignee: Merck & Co., Inc.Inventors: Daniel F. Veber, S. Dale Lewis, Jules A. Shafer, Dong-Mei Feng, Ruth F. Nutt, Stephen F. Brady
-
Patent number: 5629324Abstract: Compounds of the invention have the following structure: ##STR1## for example ##STR2## These compounds inhibit thrombin and associated thrombosis.Type: GrantFiled: April 10, 1995Date of Patent: May 13, 1997Assignee: Merck & Co., Inc.Inventors: Joseph P. Vacca, William C. Lumma, Stephen F. Brady, Thomas J. Tucker
-
Patent number: 5510369Abstract: Compounds of the invention have the following structure: ##STR1## for example ##STR2## These compounds inhibit thrombin and associated thrombosis.Type: GrantFiled: July 22, 1994Date of Patent: April 23, 1996Assignee: Merck & Co., Inc.Inventors: William C. Lumma, Roger M. Freidinger, Stephen F. Brady, Philip E. Sanderson, Dong-Mei Feng, Terry A. Lyle, Kenneth J. Stauffer, Thomas J. Tucker, Joseph P. Vacca
-
Patent number: 5374622Abstract: A fibrinogen receptor antagonist of the formulaAc-Cys-Asn-Pro-(L-AMF)-Gly-Asp-Cys-OHorAc-Cys-Asn-(DiMeTzl)-(L-AMF)-Gly-Asp-Cys-OH.Type: GrantFiled: January 28, 1993Date of Patent: December 20, 1994Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber, Mark E. Duggan
-
Patent number: 5338723Abstract: A fibrinogen receptor antagonist of the formula ##STR1## wherein XX represents a synthetic alpha-amino acid containing a linear side chain and ZZ represents a sequence of 1, 2, 3 or 4 amino acids.Type: GrantFiled: September 21, 1992Date of Patent: August 16, 1994Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber, Mark E. Duggan
-
Patent number: 5204328Abstract: Atrial natriuretic factor analogs containing N-alkylated amino acids and showing enhanced potency and increased metabolic stability. These analogs have natriuretic, diuretic and vasorelaxant activity, making them suitable for treating congestive heart failure and renal hypertension.Type: GrantFiled: November 5, 1991Date of Patent: April 20, 1993Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber, Theresa M. Williams
-
Patent number: 5091366Abstract: Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro, HAr-Pro, Dly-Pro, Arg-Pro, Lys-BAr, Arg-Pro, CyA-CyA, Cys-Cys, or with .alpha.-aminoheptanoic acid result in analogs of ANF having increased potencies and metabolic stability.Type: GrantFiled: June 4, 1990Date of Patent: February 25, 1992Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Terrence M. Ciccarone, Stephen F. Brady, Daniel F. Veber
-
Patent number: 5061693Abstract: A fibrinogen receptor antagonist compound of the structure:A--B--C--Gly--Asp--D--E (I)wherein A, B, C, D and E are preferably defined as follows:A is L-asparagine, D-asparagine or acylated asparagineB is an L-or D-isomer of proline, thioproline, .beta.,.beta.-dimethylthioproline, or N-methylalanine;C is arginine;D is phenylalanine, tryptophan .alpha.-naphthylalanine, .beta.-napthlalanine, arginine or lysine; andE is OH.Type: GrantFiled: July 28, 1989Date of Patent: October 29, 1991Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber
-
Patent number: 5023233Abstract: A fibrinogen receptor antagonist of the formula: ##STR1## wherein A, B, C, D, E, R, R.sup.1 and X-Y are preferably defined as follows:A is acylamido;R and R.sup.1 are H;X-Y is S--S;B is L-asparagine;C is proline or thioproline or .beta., .beta.-dimethylthroprolineD is arginine; andE is COOH.Type: GrantFiled: July 28, 1989Date of Patent: June 11, 1991Assignee: Merck & Co., Inc.Inventors: Ruth F. Nutt, Stephen F. Brady, Daniel F. Veber
-
Patent number: 4816443Abstract: Novel peptides having potent natriuretic activity are disclosed with the following amino acid sequence: ##STR1## wherein Z is H, acetyl, Boc or Ser-Leu, E is Phe, NMP, OMT, ChA, F is Gly or DAl, G is Ala or Gly, H is Arg or DAr, Pro, Lys or Dly, I is Ile, Met, MeO, MO.sub.2, Leu, Nle, or Val, J is Aib, .alpha.MG or .alpha.MA, K is Arg or Lys, L is Ile or Val, M is Aib, Gly, Ala or DAl, N is Ala, NMA, Pro, Phe or NMP, O is Gln, DGl, Ala or DAl, P is Ser, His, Arg or Lys, Q is Gly, Pro, Ala or Dal, R is Leu, Phe or ChA, S is Gly, Ala or Dal, Arg or DAr, T is Asn DAs, Ala or Dal, U is Ser, DSe, Ala or DAl, V is Phe, DPh, Ala or DAl, Y is -OH or -NH.sub.2 and n is 0 or 1. Also included are the lower alkyl esters and the physiologically acceptable metal salts and acid addition salts of the foregoing peptides. Unless indicated otherwise all optically active amino acids have the L-configuration.Type: GrantFiled: May 19, 1987Date of Patent: March 28, 1989Assignee: Merck & Co., Inc.Inventors: Stephen F. Brady, Ruth F. Nutt
-
Patent number: 4663435Abstract: Somatostatin analogs are prepared wherein a cyclic hexapeptide contains a bridged grouping which replaces eight of the ring amino acids of somatostatin. The bridged cyclic hexapeptides are easier to synthesize, have a longer duration of activity, and many have a greater level of activity than somatostatin. The compounds have the properties of selectively inhibiting the release of glucagon, growth hormone and insulin. Certain of the compounds also are capable of inhibiting the release of gastric acid secretions. The compounds are particularly useful in the treatment of acromegaly, diabetes, diabetic retinopathy and peptic ulcers. These bridged cyclic hexapeptides are prepared by the solid phase method.Type: GrantFiled: June 24, 1985Date of Patent: May 5, 1987Assignee: Merck & Co., Inc.Inventor: Stephen F. Brady